Evidence map›Paper›PMID 36271231›Full record

ArticleScientific reports2022

Visualization of estimated prevalence of CES-D positivity accounting for background factors and AIS scores.

Takashi Matsuyama, Akira Narita, Masaki Takanashi, Mana Kogure, Shuichi Sato, Tomohiro Nakamura, Hideo Nakane, Soichi Ogishima, Fuji Nagami, Naoki Nakaya and 3 more

Abstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Takashi MatsuyamaToyota Central Research and Development Laboratories Inc., Nagakute, 480-1192, Japan. e1215@mosk.tytlabs.co.jp.
Akira NaritaTohoku Medical Megabank Organization, Tohoku University, Sendai, 980-8573, Japan.
Masaki TakanashiToyota Central Research and Development Laboratories Inc., Nagakute, 480-1192, Japan.
Mana KogureTohoku Medical Megabank Organization, Tohoku University, Sendai, 980-8573, Japan.
Shuichi SatoToyota Central Research and Development Laboratories Inc., Nagakute, 480-1192, Japan.
Tomohiro NakamuraTohoku Medical Megabank Organization, Tohoku University, Sendai, 980-8573, Japan.
Hideo NakaneToyota Central Research and Development Laboratories Inc., Nagakute, 480-1192, Japan.
Soichi OgishimaTohoku Medical Megabank Organization, Tohoku University, Sendai, 980-8573, Japan.
Fuji NagamiTohoku Medical Megabank Organization, Tohoku University, Sendai, 980-8573, Japan.
Naoki NakayaTohoku Medical Megabank Organization, Tohoku University, Sendai, 980-8573, Japan.
Kozo TannoIwate Tohoku Medical Megabank Organization, Iwate Medical University, Yahaba-Cho, Iwate, 028-3694, Japan.
Takao ImaedaToyota Central Research and Development Laboratories Inc., Nagakute, 480-1192, Japan.
Atsushi HozawaTohoku Medical Megabank Organization, Tohoku University, Sendai, 980-8573, Japan. hozawa@megabank.tohoku.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Development of methods for population screening is necessary to improve the efficiency of secondary prevention of diseases. Until now, a common cutoff has been used for all people in the data set. However, if big data for health information can be used to modify individual cutoffs according to background factors, it may avoid wasting medical resources. Here we show that the estimated prevalence of the Center for Epidemiologic Studies Depression Scale positivity can be visualized by a heatmap using background factors from epidemiological big data and scores from the Athens Insomnia Scale. We also show that cutoffs based on the estimated prevalence can be used to decrease the number of people screened without decreasing the number of prevalent cases detected. Since this method can be applied to the screening of different outcomes, we believe our work can contribute to the development of efficient screening methods for various diseases.

Indexed as

DepressionSleep Initiation and Maintenance DisordersHumansMass ScreeningPrevalence

Identifiers

PMID36271231
PMCPMC9586984

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.